Telix Pharmaceuticals Limited · 22 hours ago
Director, Tumour Microenvironment Research
United States
Full-time
Remote
Director/Executive
10+ years expTelix Pharmaceuticals is a dynamic, fast-growing radiopharmaceutical company focused on precision medicine through targeted radiation. The Director of Tumour Microenvironment Research will lead discovery research projects aimed at enhancing pipeline assets and developing new products to meet clinical and commercial needs in oncology and rare diseases.
Biotechnology
Responsibilities
Developing and managing a TME research plan in line with Telix’s strategic & commercial needs
Creation of commercially-relevant TME research plans to identify synergies between pipeline programs & research outcomes, to evaluate new cancer targets and to seek ways to add value to existing products in the pipeline
Working collaboratively with commercial leads, development program heads and other R&D leadership to identify clinical and commercial opportunities of interest and prioritize research accordingly
Demonstrated active identification and pursuit of academic or commercial collaborations and novel developments to support the research program. Including evaluating in-licensing opportunities
Leading and Managing research projects with a commercial mindset to deliver meaningful research & clinical outcomes and effective delivery
Establishing effective plans and reporting milestones to deliver impactful research producing measurable research outcomes (e.g. data, patents, publications, conference abstracts) that directly support the design of new clinical studies
Building key relationships, network partnerships and collaborations through research partners, in-house and externally sourced resources to support the conduct of research projects
Manage the delivery of projects on time and budget; building cost-effective resourcing plans, including grant applications where appropriate, for implementation and achievement of research goals
Providing scientific thought leadership on developments in the TME field, encouraging strategic partnerships with industry and academia to identify new opportunities
Embody the role of ‘subject matter expert’ regarding Cancer Target biology for radiation delivery via in-depth literature reviews, analysis of existing cancer biomarker datasets or the conduct of bespoke target validation studies as required
Evaluate scientific opportunities to optimize the performance of existing assets by expanding into new indications of interest (target evaluations), dosing improvements or drug combinations as suitable
Identifying validated or novel cancer targets of interest that are suitable for delivery of a diagnostic or therapeutic radiation payload
Based on understanding of TME and radiobiology; make recommendations for the selection of optimal radioisotope payloads for each targeting agent format
Through self-directed research, attendance at conferences or requests from programs, identify & prioritise prospective new opportunities and review and present data packages on targets or agents suitable for exploration in preclinical studies
Supporting internal programs, key collaborations and potential commercial partnerships by providing technical support and advice
Partnering with a range of internal stakeholders from R&D colleagues, preclinical, clinical, project teams and into development streams and strategic alliances and business development to provide scientific and SME input. Contributing to evaluation of opportunities and building new partnerships for development and commercial opportunities
Qualification
Required
Post-graduate scientific qualifications required (minimum masters' degree / PhD preferred)
Relevant applied research experience in cancer biology, tumour microenvironment, oncology, radiobiology or radiopharmaceutical drug development projects
At least 10 years of relevant R&D experience with at least 2 years in clinical or commercial drug development. With a solid understanding of the pharmaceutical research environment and development and lifecycle management
Proven prior experience managing complex technical research programs and successful 3rd party academic or commercial collaborations
Inclusive mindset: Demonstrate an understanding and appreciation for diversity, and actively work to create an inclusive environment where everyone feels valued and respected
Creativity and innovation: Possess a willingness to think outside the box and come up with unique and creative solutions to challenges
Commitment to excellence: Take pride in your work and consistently strive for excellence in everything you do
Results-oriented: Driven to achieve goals and objectives, with a strong focus on delivering measurable results
Ethical behavior: Act with integrity and demonstrate a commitment to ethical behavior in all interactions with colleagues and stakeholders
Adaptability: Comfortable working in a dynamic environment, able to adjust to changing priorities, and willing to take on new challenges
Strong communication skills: Able to communicate effectively with colleagues and stakeholders at all levels, using clear and concise language
Collaboration: Work effectively as part of a team, actively sharing knowledge and expertise to achieve common goals
Resilience: Demonstrate the ability to bounce back from setbacks and persevere in the face of challenges
Continuous learning: Show a commitment to ongoing learning and professional development, continually seeking out opportunities to expand your knowledge and skills
Benefits
Competitive salaries
Annual performance-based bonuses
An equity-based incentive program
Generous vacation
Paid wellness days
Support for learning and development
Company
Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic ('theranostic') radiopharmaceuticals.
1001-5000 employees
Funding
Current Stage
Public CompanyTotal Funding
$493.27MKey Investors
Australian Government
2024-07-23Post Ipo Debt· $429.77M
2022-04-04Grant· $23M
2020-03-16Grant· $0.5M
Leadership Team
Christian Behrenbruch
Group CEO and Managing Director
Kevin Richardson
CEO Americas
Recent News
Benzinga.com
2026-01-22
legacy.thefly.com
2026-01-21
BioWorld Financial Watch
2026-01-21
Company data provided by crunchbase